Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Nebulised Beclomethasone Dipropionate Plus as Needed Salbutamol vs as Needed Salbutamol or as Needed Salbutamol/Beclomethasone Fixed Combination in Young Children With Asthma Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be enrolled into the 2-week placebo run-in period if they meet all the following criteria:~* Age ≥ 1 year and ≤ 4 years.~* At least 3 episodes of wheeze or asthma-like symptoms in the 6 months preceding the study entry.~* A cooperative attitude and ability to be trained to inhale correctly from the device and to complete the diary cards.~* Written parental/guardian informed consent obtained.~Patients will be then randomised to the treatment period if they meet all the previous criteria plus:~* Presence in at least 7 days out of the 14 days of the run-in period of at least one of the following symptoms: wheeze, cough or shortness of breath; or had required at least one dose of relief salbutamol.~Exclusion Criteria:~* History of severe asthma exacerbation or exacerbations requiring hospitalisation in the previous 4 weeks.~* Symptomatic infection of the airways requiring treatment with antibiotics or antimycotics in the previous 4 weeks.~* Treatment with inhaled steroids in the previous 4 weeks or oral steroids in the previous 8 weeks.~* Treatment with methyl-xantine derivatives in the previous 4 weeks.~* Treatment with long-acting β2-agonists in the previous 2 weeks.~* Changes in asthma medications taken on regular basis in the previous 4 weeks.~* Symptoms of asthma limited to seasonal allergen exposure.~* History of clinically significant cardiac, renal, neurologic, hepatic, endocrine or pulmonary disease (except asthma), or laboratory testing abnormalities, whose sequelae and/or treatments can interfere with the results of the present study.~* Evidence of pulmonary malformations.~* Evidence of immunological deficiency (patients to be withdrawn if diagnosed during the study).~* Cancer or any other chronic disease with prognosis \< 2 years.~* Hypersensitivity to inhaled corticosteroids.~* Participation in another trial in the last 4 weeks.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Beclomethasone dipropionate (Type: EXPERIMENTAL): None
- Beclomethasone dipropionate/Salbutamol combination (Type: EXPERIMENTAL): None
- Salbutamol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).